📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Fumapharm

1.1 - Company Overview

Fumapharm Logo

Fumapharm

Headquarter: Switzerland
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of pharmaceuticals as a privately held company.

Products and services

🔒

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Fumapharm

Nuvig Therapeutics Logo

Nuvig Therapeutics

HQ: United States Website
  • Description: Provider of therapies that induce natural mechanisms to restore immune homeostasis, including NVG-2089, a recombinant, non-immunosuppressive immunomodulator targeting type II Fc receptors to reduce autoimmune dysregulation, in clinical development for inflammatory myopathies and dermatologic autoimmune diseases; recombinant proteins activating immune regulatory receptors; and engineered therapeutic antibodies for autoimmune diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Nuvig Therapeutics company profile →
ADMA Biologics Logo

ADMA Biologics

HQ: United States Website
  • Description: Provider of plasma-based biologics, including ASCENIV IVIG for primary immunodeficiency disease (PIDD) and other immune-compromised conditions; BIVIGAM IVIG for primary humoral immunodeficiency (PI); Nabi-HB hyperimmune globulin to prevent hepatitis B infection following exposure; and ADMA BioCenters, a network of plasma collection centers supplying high-quality plasma for immunoglobulin manufacturing.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full ADMA Biologics company profile →
Reneo Pharmaceuticals Logo

Reneo Pharmaceuticals

HQ: United States Website
  • Description: Provider of therapies in development for rare genetic mitochondrial and orphan metabolic diseases. Develops mavodelpar (REN001) for primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD), with a global Phase 2b trial in PMM and completed exploratory Phase 1b trials in LC-FAOD and McArdle disease.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Reneo Pharmaceuticals company profile →
Repertoire Logo

Repertoire

HQ: United States Website
  • Description: Provider of clinical-stage immune medicines, offering the DECODE platform to identify TCRs and disease-relevant epitopes across all human HLAs; off-the-shelf TCR bispecific therapeutics that engage T cells via tumor-specific epitopes and an anti-CD3 moiety; mRNA cancer vaccines delivered via lipid nanoparticles; and mRNA tolerizing vaccines to induce T-cell anergy and expand regulatory T cells for autoimmune diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Repertoire company profile →
Philogen Logo

Philogen

HQ: Italy Website
  • Description: Provider of biopharmaceuticals targeting angiogenesis and tumor-associated blood vessels for the treatment of cancer and other serious conditions, with a pipeline including Nidlegy (clinical-stage), Fibromun (in clinical development), Darleukin for selective delivery to tumor sites, Dekavil and Dodekin targeting vascular antigens, and Onco IX utilizing vascular targeting.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Philogen company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Fumapharm

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Fumapharm

2.2 - Growth funds investing in similar companies to Fumapharm

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Fumapharm

4.2 - Public trading comparable groups for Fumapharm

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Fumapharm

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Fumapharm

What does Fumapharm do?

Fumapharm is a provider of pharmaceuticals as a privately held company.

Who are Fumapharm's competitors?

Fumapharm's competitors and similar companies include Nuvig Therapeutics, ADMA Biologics, Reneo Pharmaceuticals, Repertoire, and Philogen.

Where is Fumapharm headquartered?

Fumapharm is headquartered in Switzerland.

How many employees does Fumapharm have?

Fumapharm has 1,000 employees 🔒.

When was Fumapharm founded?

Fumapharm was founded in 2010 🔒.

What sector and industry vertical is Fumapharm in?

Fumapharm is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Fumapharm

Who are the top strategic acquirers in Fumapharm's sector and industry

Top strategic M&A buyers and acquirers in Fumapharm's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Fumapharm?

Top strategic M&A buyers groups and sectors for Fumapharm include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Fumapharm's sector and industry vertical

Which are the top PE firms investing in Fumapharm's sector and industry vertical?

Top PE firms investing in Fumapharm's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Fumapharm's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Fumapharm's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Fumapharm's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Fumapharm include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Fumapharm's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Fumapharm?

The key public trading comparables and valuation benchmarks for Fumapharm include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Fumapharm for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Fumapharm with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Fumapharm's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Fumapharm with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Fumapharm's' sector and industry vertical?

Access recent funding rounds and capital raises in Fumapharm's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Fumapharm